相关实验视频

Updated: Jun 8, 2025

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

在遗传分类时代,MYC/BCL2双表达在DLBCL的预后意义在于DLBCL的预后意义

Yi-Fan Wu¹, Qun-Hui Yuan¹, Hao-Rui Shen¹

¹Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.

|November 4, 2024

概括

在扩散性大B细胞淋巴瘤 (DLBCL) 中,双重表达 (DE) 影响生存率,特别是在EZB和其他亚型中. 了解DE机制对于改善这些DLBCL患者的治疗结果至关重要.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

双表达 (DE) 是一个公认的不良预后因素在扩散大B细胞淋巴瘤 (DLBCL).
在不同的遗传亚型中,DE的预后意义及其潜在机制需要进一步研究.

研究的目的:

评估DLBCL中DE的预后价值,考虑遗传亚型.
探索潜在的生物学机制,有助于DE对患者结果的影响.

主要方法:

对来自医院队列的246名DLBCL患者和来自外部队列的930名患者的回顾性分析.
评估与DE和遗传亚型相关的总生存 (OS) 和无进展生存 (PFS).
探索突变概况和RNA测序数据,用于途径分析.

主要成果:

在DLBCL中,DE与不利的OS和PFS显著相关,特别是在EZB和OTHER亚型中.
在突变概况上,DEL患者与MCD亚型有相似之处.
在LED患者中,RNA测序揭示了上调的瘤增殖路径和下调的免疫相关和细胞死亡路径.

结论:

在特定的DLBCL遗传亚型 (EZB,OTHER) 中,DE仍然具有显著的不良预后影响.
不同的分子途径,包括改变的免疫反应和细胞增殖,可能是DL患者观察到的不良结果的基础.
对这些机制的进一步研究可以确定DLBCL的新型治疗点.

关键词:

一个生物机制的生物机制.扩散的大B细胞淋巴瘤双重表达方式双重表达方式遗传亚型遗传亚型遗传亚型预后预后预后

更多相关视频

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...